

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: October 21, 2024**

**Commission File Number: 001-39307**

---

**Legend Biotech Corporation**

(Exact Name of Registrant as Specified in its Charter)

---

**2101 Cottontail Lane  
Somerset, New Jersey 08873**  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

On October 21, 2024, Legend Biotech Corporation (the “Company”) held its 2024 Annual General Meeting of Shareholders (the “Meeting”). The voting results are attached hereto as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625, 333-272222 and 333-278050) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

## **EXHIBITS**

Exhibit 99.1 — Voting Results of Annual General Meeting

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**LEGEND BIOTECH CORPORATION**

Date: October 21, 2024

By: /s/ Ying Huang

Name: Ying Huang, Ph.D.

Title: Chief Executive Officer

### Voting Results of 2024 Annual General Meeting

At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on October 21, 2024 (the "AGM"), the Company's shareholders:

- received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2023;
- ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending December 31, 2024;
- re-elected each of Ms. Ye Wang, Dr. Darren Xiaohui Ji, Dr. Ying Huang and Mr. Tomas Heyman to serve as a Class I director for a three-year term;
- approved the amendment and restatement of the Company's 2020 Restricted Shares Plan to increase the aggregate number of ordinary shares reserved for issuance by 15,000,000 ordinary shares; and
- authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

A total of approximately 351,102,656 ordinary shares, including those underlying ADSs, representing approximately 95.3% of the ordinary shares issued and outstanding as of September 17, 2024, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

Resolutions	For		Against		Abstain	
	Votes	%	Votes	%	Votes	%
<b>Reception of Audited Financial Statements</b>	351,026,682	95.238%	35,060	0.010%	40,914	0.011%
<b>Ratification of appointment of Ernst &amp; Young LLP as Independent Auditor for Fiscal Year 2024</b>	351,070,748	95.250%	3,276	0.001%	28,632	0.008%
<b>Election of Directors</b>						
Ye Wang (Class I)	254,083,338	68.936%	96,987,136	26.314%	32,182	0.009%
Dr. Darren Xiahui Ji (Class I)	344,087,858	93.356%	6,982,614	1.894%	32,184	0.009%
Dr. Ying Huang (Class I)	350,256,394	95.029%	814,082	0.221%	32,180	0.009%
Tomas Heyman (Class I)	344,761,778	93.539%	6,307,538	1.711%	33,340	0.009%
<b>Amendment and Restatement of 2020 Restricted Shares Plan</b>	347,474,014	94.275%	3,601,752	0.977%	26,890	0.007%
<b>Authorization of Directors and Officers</b>	350,780,616	95.172%	191,268	0.052%	130,772	0.035%